Lucentis (Ranibizumab) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The lucentis (ranibizumab) market size has grown strongly in recent years. It will grow from $3.74 million in 2025 to $3.96 million in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to clinical success in macular degeneration, rising diabetic retinopathy cases, aging population, ophthalmologist adoption, regulatory approvals in eye care.

The lucentis (ranibizumab) market size is expected to see strong growth in the next few years. It will grow to $4.87 million in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to growth in retinal disease prevalence, increasing access to eye care services, expansion of biosimilar competition, rising awareness of early diagnosis, technological advances in injection delivery. Major trends in the forecast period include sustained use of anti vegf therapies, rising treatment of retinal vascular disorders, growing preference for intravitreal injections, expansion of ophthalmology specialty clinics, increased focus on vision preservation.

The rising prevalence of eye-related disorders is expected to drive the growth of the Lucentis (ranibizumab) market in the coming years. Eye-related disorders encompass a variety of conditions that affect the eyes and impair their proper functioning. The increasing occurrence of these disorders is attributed to aging, genetic predisposition, unhealthy lifestyle choices such as smoking and poor diet, and environmental factors like prolonged sun exposure or extended digital screen use. Lucentis acts by inhibiting vascular endothelial growth factor (VEGF), a protein that causes abnormal blood vessel growth and leakage in the retina, which is a major contributor to conditions such as age-related macular degeneration (AMD) and diabetic macular edema (DME). For example, in 2024, the National Eye Institute, a US government agency, projected that 2.2 million Americans will be blind by 2030. Therefore, the growing prevalence of eye-related disorders is fueling the expansion of the Lucentis (ranibizumab) market.

The increase in healthcare spending is also expected to support the growth of the Lucentis (ranibizumab) market. Healthcare spending refers to the total financial resources allocated by individuals, governments, private insurers, and other organizations for healthcare services and products. This increase is driven by an aging population, advancements in medical technologies, rising prevalence of chronic diseases, and higher demand for healthcare services. Greater healthcare spending enhances the accessibility and availability of Lucentis (ranibizumab) by supporting its widespread use in treating retinal conditions like AMD and DME, ensuring healthcare systems can allocate resources for its coverage, reimbursement, and distribution, ultimately improving patient outcomes and reducing the long-term burden of vision loss. For instance, in May 2024, the Office for National Statistics, a UK government department, reported that healthcare spending in the UK grew by 5.6% between 2022 and 2023, compared to 0.9% growth in 2022. The total UK healthcare expenditure was approximately $317.63 billion (£292 billion) in 2023. As a result, rising healthcare spending is driving the growth of the Lucentis (ranibizumab) market.

Key players in the Lucentis (ranibizumab) market are focusing on developing biosimilars to offer more affordable alternatives to the original branded product. Biosimilars are biologic medicines that are highly similar to an already approved reference biologic in structure, efficacy, and safety, with no clinically meaningful differences. For example, in April 2024, Formycon AG, a Germany-based biotechnology company, and Bioeq AG, a Switzerland-based biotechnology company, launched their biosimilar version of Lucentis (ranibizumab), called FYB201, in Canada and Switzerland. Health Canada granted marketing authorization under the name Ranopto, while Swiss Medic approved it as Ranivisio. The approval and launch of FYB201 aim to provide more affordable treatment options for patients with retinal diseases. It works by inhibiting vascular endothelial growth factor A (VEGF-A), a protein that promotes abnormal blood vessel growth in the retina, which can cause swelling, leakage, and vision impairment.

Major companies operating in the lucentis (ranibizumab) market are F.Hoffmann-La Roche Ltd, Novartis AG.

North America was the largest region in the lucentis (ranibizumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lucentis (ranibizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lucentis (ranibizumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the Lucentis market by increasing costs for imported biologic substances, prefilled syringe components, and cold chain logistics. These impacts are more visible in regions dependent on imported ophthalmic biologics, particularly asia pacific and latin america. Hospital and clinic procurement costs have increased, affecting treatment affordability. However, tariffs have driven local packaging and distribution partnerships. This supports supply continuity and improves regional market resilience.

The lucentis (ranibizumab) market research report is one of a series of new reports that provides lucentis (ranibizumab) market statistics, including lucentis (ranibizumab) industry global market size, regional shares, competitors with a lucentis (ranibizumab) market share, detailed lucentis (ranibizumab) market segments, market trends and opportunities, and any further data you may need to thrive in the lucentis (ranibizumab) industry. This lucentis (ranibizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lucentis (ranibizumab) is a prescription drug used to treat a range of eye conditions involving abnormal blood vessel growth in the retina. It is a recombinant monoclonal antibody fragment that works by inhibiting vascular endothelial growth factor (VEGF), a protein responsible for the formation of abnormal blood vessels.

The main forms of Lucentis (ranibizumab) available in the market are single-use prefilled syringes and single-use glass vials. A single-use prefilled syringe is a medical device containing a pre-measured dose of medication, ready for immediate use. Its applications include age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, myopic choroidal neovascularization, and uveitis. Key end-users include hospitals, clinics, ambulatory surgical centers, and other healthcare facilities.

The lucentis (ranibizumab) market consists of sales of lucentis intravitreal injection and lucentis for biosimilars. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.